08.03.2020
|
Articles
About Us
中文网站
Offices
Careers
Client Advantage
Client Login
08.03.2020
|
Articles
The cannabidiol (CBD) industry has seen a new wave of consumer class actions. The industry is poised to see further cases, especially as the market for CBD-containing products grows. At the same time, federal courts are increasingly placing these class actions on pause, staying them to allow the U.S. Food and Drug Administration (FDA) to issue rulemaking to clarify uniform, national standards for CBD product labeling. Already, three class actions have been stayed pending forthcoming agency action.
Background
CBD consumer litigation is on the rise following a November uptick in warning letters to companies for health-related claims. These consumer suits try to take advantage of these letters and challenge a number of claims, some of which are the subject of the letters and others are new. One set of these cases asserts that the amount of CBD on the label fails to match the product’s composition. Other class actions allege that CBD, especially in food and beverage products, is illegal to sell—regardless of any claim.
Click here to read the full article on Cannabis Business Executive.
Partner
D +1.310.788.3220
D +1.415.344.7003
We use cookies on this website to enhance your user experience and to improve the quality of our site. By continuing to use this website, you are demonstrating your consent to the placement and use of cookies as described in our Cookie Policy.